Stock IKT INHIBIKASE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Inhibikase Therapeutics, Inc.

Equities

IKT

US45719W2052

Market Closed - Nasdaq
Other stock markets
 21:30:01 06/05/2024 BST 		5-day change 1st Jan Change
1.29 USD -7.19% Intraday chart for Inhibikase Therapeutics, Inc. -18.87% +1.57%
04-03 Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension CI
03-28 Transcript : Inhibikase Therapeutics, Inc., 2023 Earnings Call, Mar 28, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
GL
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
GL
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
CI
Transcript : Inhibikase Therapeutics, Inc., 2023 Earnings Call, Mar 28, 2024
Earnings Flash (IKT) INHIBIKASE THERAPEUTICS Posts 2023 Revenue $260,501
MT
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
GL
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
GL
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib At the 2024 International Conference Onzheimer's and Parkinson's Diseases and Related Neurological Disorders
CI
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
GL
Maxim Initiates Inhibikase Therapeutics With Buy Rating, Price Target is $8
MT
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
GL
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
AQ
Inhibikase Therapeutics Announces Preliminary Outcomes of Its Pre-Nda Meeting with the Fda on the Pathway for Approval for Ikt-001Pro in Blood and Gastrointestinal Cancers
CI
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
AQ
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
GL
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
AQ
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
CI
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
GL
Inhibikase Therapeutics Announces Chief Financial Officer Changes, Effective End of the First Quarter of 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IKT Stock
  4. News Inhibikase Therapeutics, Inc.